Decazes Pierre, Bohn Pierre
Department of Nuclear Medicine, Henri Becquerel Cancer Center, 76000 Rouen, France.
LITIS-QuantIF-EA (Equipe d'Accueil) 4108, IRIB, Faculty of Medicine, University of Rouen, 76000 Rouen, France.
Cancers (Basel). 2020 Feb 6;12(2):371. doi: 10.3390/cancers12020371.
Immunotherapy by using immune checkpoint inhibitors is a revolutionary development in oncology. Medical imaging is also impacted by this new therapy, particularly nuclear medicine imaging (also called radionuclide imaging), which uses radioactive tracers to visualize metabolic functions. Our aim was to review the current applications of nuclear medicine imaging in immunotherapy, along with their limitations, and the perspectives offered by this imaging modality. : Articles describing the use of radionuclide imaging in immunotherapy were researched using PubMed by April 2019 and analyzed. : More than 5000 articles were analyzed, and nearly 100 of them were retained. Radionuclide imaging, notably F-FDG PET/CT, already has a major role in many cancers for pre-therapeutic and therapeutic evaluation, diagnoses of adverse effects, called immune-related adverse events (IrAE), and end-of-treatment evaluations. However, these current applications can be hindered by immunotherapy, notably due to atypical response patterns such as pseudoprogression, which is defined as an increase in the size of lesions, or the visualization of new lesions, followed by a response, and hyperprogression, which is an accelerated tumor growth rate after starting treatment. To overcome these difficulties, new opportunities are offered, particularly therapeutic evaluation criteria adapted to immunotherapy and immuno-PET allowing us to predict responses to immunotherapy. Moreover, some new technological solutions are also promising, such as radiomic analyses and body composition on associated anatomical images. However, more research has to be done, notably for the diagnosis of hyperprogression and pseudoprogression. : Immunotherapy, by its major impact on cancer and by the new patterns generated on images, is revolutionary in the field of medical images. Nuclear medicine imaging is already established and will be able to help meet new challenges through its plasticity.
使用免疫检查点抑制剂进行免疫治疗是肿瘤学领域的一项革命性进展。医学成像也受到这种新疗法的影响,特别是核医学成像(也称为放射性核素成像),它使用放射性示踪剂来可视化代谢功能。我们的目的是回顾核医学成像在免疫治疗中的当前应用、其局限性以及这种成像方式所提供的前景。:通过在PubMed上检索截至2019年4月描述放射性核素成像在免疫治疗中应用的文章并进行分析。:分析了5000多篇文章,保留了其中近100篇。放射性核素成像,尤其是F-FDG PET/CT,在许多癌症的治疗前和治疗评估、不良反应(称为免疫相关不良事件,IrAE)的诊断以及治疗结束评估中已经发挥了重要作用。然而,这些当前应用可能会受到免疫治疗的阻碍,特别是由于非典型反应模式,如假进展(定义为病变大小增加或新病变的可视化,随后出现反应)和超进展(即开始治疗后肿瘤生长加速)。为克服这些困难,提供了新的机会,特别是适用于免疫治疗的治疗评估标准和免疫PET,使我们能够预测对免疫治疗的反应。此外,一些新技术解决方案也很有前景,如基于相关解剖图像的放射组学分析和身体成分分析。然而,还需要进行更多研究,特别是针对超进展和假进展的诊断。:免疫治疗因其对癌症的重大影响以及在图像上产生的新模式,在医学图像领域具有革命性。核医学成像已经确立,并将能够通过其可塑性帮助应对新挑战。